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Abstract
Elevated latent prenatal steroidogenic activity has been found in the amniotic ﬂuid of autistic boys, based on measuring
prenatal androgens and other steroid hormones. To date, it is unclear if other prenatal steroids also contribute to autism
likelihood. Prenatal oestrogens need to be investigated, as they play a key role in synaptogenesis and corticogenesis during
prenatal development, in both males and females. Here we test whether levels of prenatal oestriol, oestradiol, oestrone and
oestrone sulphate in amniotic ﬂuid are associated with autism, in the same Danish Historic Birth Cohort, in which prenatal
androgens were measured, using univariate logistic regression (n= 98 cases, n= 177 controls). We also make a like-to-like
comparison between the prenatal oestrogens and androgens. Oestradiol, oestrone, oestriol and progesterone each related to
autism in univariate analyses after correction with false discovery rate. A comparison of standardised odds ratios showed that
oestradiol, oestrone and progesterone had the largest effects on autism likelihood. These results for the ﬁrst time show that
prenatal oestrogens contribute to autism likelihood, extending the ﬁnding of elevated prenatal steroidogenic activity in
autism. This likely affects sexual differentiation, brain development and function.
Introduction
The male-biased prevalence of autism [1, 2], together with
the ﬁnding that autistic girls have a higher mutational load
than autistic boys [3–5], suggests that males have a higher
likelihood of developing autism. The sex ratio in autism
diagnoses persists even after taking into account under- and/
or mis-diagnosis, as well as camouﬂaging in females, with
males being three times more likely to have the condition
[6]. This implicates mechanisms of sexual differentiation in
the development of autism. Five recent ﬁndings support this
inference.
First, autistic women have atypical brain structure in
sexually dimorphic regions, when assessed via magnetic
resonance imaging and compared to neurotypical controls
[7]. Second, functional connectivity in the brain of males
with autism shows both hypermasculine and hyperfeminine
patterns, when assessed in relation to neurotypical sex dif-
ferences [8]. Third, autistic people show a masculinised
shift in scores on two key sexually dimorphic psychological
traits, empathy and systemising, a ﬁnding that has been
replicated in a big data study of 36,000 autistic people
[9, 10]. Fourth, autistic women have elevated androstene-
dione levels, the precursor to testosterone [11]. Finally,
ﬁfth, autistic children have hypermasculine facial features,
as rated using three-dimensional photogrammetry [12].
Although autism is strongly heritable and sex-associated
genetic mechanisms could contribute to this implication of
sexual differentiation in autism [2, 5], prenatal hormone
exposure and a brief surge in foetal testosterone are critical
for sexual differentiation and masculinisation in humans
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[13, 14]. In line with this, we previously found elevated
steroidogenic activity during this prenatal masculinisation
window (PMW) in the amniotic ﬂuid of autistic boys [15].
Subsequently, three very large epidemiological studies
revealed a link between autism and maternal polycystic
ovarian syndrome (PCOS), a condition associated with
androgenic excess [16–18]. Consistently with this, the
2D:4D digit ratio, a marker of prenatal androgen exposure,
is also masculinised in autistic children and their parents
[19]. Finally, autistic women and their mothers have ele-
vated rates of steroid-related cancers, such as breast cancer
and ovarian cancer [20].
However, a number of studies that focused on testos-
terone have not replicated the correlation of hormonal levels
with autistic traits. First, umbilical cord testosterone mea-
sured soon after birth was not associated with the devel-
opment of autistic traits [21]. Second, salivary testosterone
during a brief period of postnatal steroid surge
(‘mini-puberty’) also did not correlate with autistic traits in
toddlers [22]. In both cases, testosterone was measured
postnatally—in the neonatal period—rather than during the
PMW, during which foetal testosterone is ﬁrst produced and
masculinisation of the brain and body commences.
This would suggest that timing is critical for the effects of
testosterone on the brain, with the late ﬁrst-early second
trimester PMW being key, rather than the neonatal period.
Finally, univariate assessment of amniotic testosterone in a
separate cohort of neurotypical children also failed to reveal
an association to autistic traits in childhood [23]. This latter
ﬁnding may reﬂect that the wider endocrine environment
outside testosterone is also signiﬁcant for autism likelihood.
While prenatal androgens are responsible for masculini-
sation in humans, prenatal oestrogens also contribute to
foetal and neonatal brain development [24], and yet these
have not been thoroughly investigated for their potential
role in autism likelihood. Oestrogens and their receptors are
widespread in the developing brain in both males and
females and regulate many neurodevelopmental processes,
including synaptogenesis, apoptosis and neuronal differ-
entiation [25–27]. Oestradiol in particular supports synapse
formation in the cortex by enhancing excitatory GABA
activity [28]. In autism, synapse formation [29], neuronal
differentiation [30] as well as the GABAergic system [31]
are all atypical. These provide clues that prenatal oestrogens
may be involved in autism. However, we still lack direct
evidence of this.
With regard to clinical studies in humans, low oestriol in
maternal serum during the second trimester of pregnancy
signiﬁcantly increases the likelihood of autism in the foetus,
as demonstrated in a large study of n= 2586 autistic
pregnancies [32]. This study may have been confounded by
a variety of pregnancy complications, such as pre-eclampsia
[33] and being small for gestational age [34], since these are
also more frequent in autism [35–37]. Thus, further study of
prenatal oestrogenic activity, particularly in foetal circula-
tion, is warranted. In addition, there is a need to compare
different prenatal oestrogens to each other, in relation to
autism likelihood.
In the present study, we measured prenatal levels of
oestriol, oestradiol, oestrone and oestrone sulphate in
amniotic ﬂuid of boys with and without autism (n= 98 and
n= 177 respectively) from the Danish Historic Birth Cohort
(HBC), in the same samples in which we had found
an elevated steroidogenic factor, following principal com-
ponent analysis of prenatal androgens and other steroid
hormones [15]. We have expanded on these ﬁndings by
assaying oestrogens and by assessments of each steroid
hormone to autism likelihood via univariate logistic
regression. We also investigated potential differences in the
aromatising capacity in autism by comparing the ratio
between androgens and oestrogens. Finally, we calculated
standardised effect sizes for all hormones assayed to date
in this cohort, in order to understand which amniotic
ﬂuid hormones make the largest contribution to autism
likelihood.
Methods
Participants and laboratory methods
The study was approved by the Danish Data Protection
Agency and The Danish Ethical Committee of Midtjylland
Region. The Danish Historic Birth Cohort was established
at Statens Serum Institute, Copenhagen with a grant from
The Danish Medical Research Foundation and The Danish
Ministry of the Interior and Health (Project no 271-05-0523/
09-060179). A full description of the cohort selection pro-
cedure is available elsewhere [15]. Brieﬂy, cases and con-
trols were drawn from singleton births between the years
1993 and 1999 inclusive, whose amniotic ﬂuid samples
were stored in the HBC. These corresponded to amnio-
centesis procedures performed between 14 and 16 weeks of
gestational age. Cases were identiﬁed from the Danish
Psychiatric Central Register using ICD-10 autism spectrum
codes F84.0 (childhood autism), F84.5 (Asperger’s syn-
drome), F84.1 (atypical autism), F84.8 (other pervasive
developmental disorder) and F84.9 (unspeciﬁed pervasive
developmental disorder). Any additional amniotic ﬂuid was
assayed for oestradiol, oestriol, oestrone, and oestrone sul-
phate, using liquid chromatography-tandem mass spectro-
scopy (Supplementary Table 1). As some individuals did
not have sufﬁcient remaining sample for analysis, the
sample size was slightly decreased. The same data quality
screening criteria that were used in the initial analysis were
applied: i.e. removal of outliers >99%, removal of records
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where duplicate assay values were >3 SD (standard devia-
tion) apart [15]. After this step, the ﬁnal sample with high-
quality data for all steroids assayed to date consisted of 98
males with autism and 177 control males. This sample was
used for all analyses in this paper, unless otherwise speci-
ﬁed (Supplementary Fig. 1).
Statistical analyses
We calculated a correlation matrix for all assayed steroid
hormones using Pearson’s correlation coefﬁcient. We also
examined the univariate distribution of each of the oestro-
gens. All hormones showed a substantial rightward skew.
We transformed the oestrogens using the Box–Cox proce-
dure to reduce their skew, as the distribution of the predictor
variable affects the statistical power of logistic regression
[38]. We used univariate logistic regression models to
determine whether each hormone separately increased aut-
ism likelihood in this cohort. As the oestrogens considered
here vary in their equilibrium association constants to the
oestrogen receptors, and therefore their potency [39, 40], we
hypothesised that if a relationship between amniotic oes-
trogens and autism was found, oestradiol would have the
largest effect size as the most potent oestrogen. Therefore,
we also considered each hormone separately, with the goal
of establishing accurate effect sizes to enable a comparison
between them, and we corrected for multiple comparisons
using the Benjamini–Hochberg false discovery rate (FDR).
To estimate and compare the aromatising capacity between
cases and controls, we calculated the aromatisation ratios,
according to previously published recommendations [41],
by log-transforming the raw concentration values and sub-
sequently subtracting them according to the following
formula:
Ratio 1= log(testosterone concentration in nmol/l)−log
(oestradiol concentration in nmol/l)
Ratio 2= log(androstenedione concentration in nmol/l)
−log(oestrone concentration in nmol/l)
We subsequently used nonparametric tests to compare these
ratios to each other (Spearman’s rank correlation coefﬁcient)
and between cases and controls (Wilcoxon rank-sum test).
Results
There were no signiﬁcant differences between groups in
maternal age at birth, paternal age at birth, birth weight,
gestational week at amniocentesis or storage time between
groups (Table 1). Raw data for each of the oestrogens are
presented in Fig. 1. Values for the median and interquartile
range as well as raw data categorised by autism diagnosis are
available in the Supplemental Information (Supplementary
Table 2). Oestradiol levels were the most predictive of an
autism diagnosis, as revealed by univariate logistic regression
(β= 0.029, FDR-adjusted q= 0.031). The same was found
for the levels of oestriol and oestrone, with both hormones
being signiﬁcantly associated to an autism diagnosis using
logistic regression (Oestriol: β= 0.025, q= 0.034; oestrone:
β= 0.029, FDR-adjusted q= 0.031) (Table 2). Oestrone
sulphate was also a nominally signiﬁcant predictor of autism
likelihood in the logistic regression model but did not
maintain statistical signiﬁcance following false discovery rate
correction (β= 0.033, p= 0.036, q= 0.065) (Table 2).
Androgens and other steroids
We revisited the previously assayed concentrations of
androgens and cortisol [15] in the same subset of samples in
which we assayed oestrogens, to understand whether the
relationship between oestrogens and autism likelihood was
similar to the relationship between androgens and autism
likelihood (Table 2, Beeswarm plots of distribution in
Supplementary Fig. 2). Of the previously analysed steroid
hormones, only progesterone was a signiﬁcant predictor of
autism diagnosis, following univariate logistic regression
and correction via FDR in this subset of the cohort (β=
0.053, FDR-adjusted q= 0.031) (Table 2).
Comparison
Pairwise correlation analysis (Pearson’s) revealed varying
degrees of similarity between the steroid hormones. The
concentrations of oestrogens were signiﬁcantly correlated
with one another at q < 0.05, adjusted for multiple compar-
isons via FDR (Fig. 2, Supplementary Table 3). Oestrone and
oestriol showed higher correlations to the other steroids than
did oestrone sulphate and oestradiol. In comparison, the
previously analysed steroid hormones formed a distinct
group, with weaker correlations to oestrogens and stronger
correlations to each other. Androstenedione and progesterone
(Pearson’s β= 0.59317, FDR-adjusted q < 0.001), oestrone
and oestrone sulphate (Pearson’s β= 0.589, FDR-adjusted
q < 0.001) were the pairs that were more closely related.
Oestradiol did not correlate with either testosterone or oestriol.
Table 1 Description of Danish Historic Birth Cohort sample
Control Autism
n= 177 n= 98
Mean ± SD Mean ± SD P value
Maternal age at birth 33.33 ± 5.15 33.53 ± 5.65 0.775
Paternal age at birth 35.30 ± 6.72 35.85 ± 7.44 0.552
Birth weight (g) 3516.81 ± 659.45 3524.55 ± 679.15 0.928
Gestational week at
amniocentesis
14.89 ± 1.91 14.90 ± 1.48 0.953
Storage time (years) 14.90 ± 1.58 14.96 ± 1.69 0.770
APGAR score > 6 97% 96%
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We also calculated standardised odds ratios (ORs) for all
analysed hormones to determine which hormones had the
largest effect on autism likelihood (Fig. 3). Each hormone
was standardised by its median and interquartile range, so
that a one-unit increase in a hormone corresponded to the
movement from the 25th to the 75th percentile of its range.
Progesterone and oestradiol had the highest standardised
ORs, with a movement from the 25th to 75th percentile of
these hormones incurring nearly a 50% increase in autism
likelihood. Oestrone and oestrone sulphate also had ORs
over 1. In contrast, increases in testosterone or androste-
nedione levels were not associated with increases in like-
lihood of diagnosis with statistical conﬁdence.
The aromatising of testosterone (Τ) to oestradiol (Ε2)
and of androstenedione (Α) to oestrone (Ε1) were
indirectly assessed by calculating their ratios, following
Fig. 1 Beeswarm plots
illustrating the distribution of
oestriol, oestradiol, oestrone and
oestrone sulphate
concentrations. Error bars
represent the interquartile range,
and the black dot represents
the median; (n CTR= 177,
n ASC= 98)
Table 2 Results of univariate
logistic regression for amniotic
steroid hormones
Regression coefﬁcient Standard error z-value p value FDR-adjusted q value
Oestriol 0.025* 0.010 2.426 0.015 0.034
Oestradiol 0.029* 0.010 2.757 0.006 0.031
Oestrone 0.029* 0.011 2.603 0.009 0.031
Oestrone sulphate 0.033 0.016 2.095 0.036 0.065
Testosterone 0.352 0.304 1.157 0.247 0.247
Androstenedione 0.444 0.270 1.648 0.100 0.128
17-OH Progesterone 0.547 0.271 2.022 0.043 0.065
Progesterone 0.053* 0.021 2.562 0.010 0.031
Cortisol 0.147 0.111 1.332 0.183 0.206
*Statistical signiﬁcance (q < 0.05), following correction via FDR
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log-transformation and subtraction of their raw values. The
two ratios were highly correlated with each other (Spear-
man’s rho= 0.5855, p < 0.001) but were not signiﬁcantly
different between autism cases and neurotypical controls
(T/E2: Wilcoxon rank-sum w= 11186, p= 0.1364) (A/E1:
Wilcoxon rank-sum w= 11032, p= 0.2038).
Discussion
This study reports the ﬁrst evidence that elevated levels of
prenatal amniotic oestradiol, oestriol and oestrone are each
associated with autism, with oestradiol levels being the
most signiﬁcant predictor of autism likelihood in univariate
logistic regression models. These ﬁndings complement
earlier observations that elevated steroidogenic activity is
associated with autism in the same samples derived from the
Danish Historic Birth cohort [15]. We also calculated
standardised ORs, in order to directly compare the effect
sizes of all amniotic steroids measured to date. We found
that oestradiol had the strongest positive effect size on
autism likelihood, followed by oestrone, oestriol and pro-
gesterone (Fig. 3). This ﬁnding appears to contradict an
earlier report by Windham et al. [32] that showed that lower
levels of oestriol in second trimester were modestly asso-
ciated with a later diagnosis of autism in the offspring.
However, our samples correspond to a slightly earlier time
point in pregnancy compared to Windham et al. (mean
gestational week= 14.9 vs. 17.2 respectively) (see Table 1)
[32], which could potentially better capture the steroid surge
during the PMW [14]. Furthermore, our samples are of
different origin, as Windham et al. assayed maternal serum,
rather than foetal amniotic ﬂuid. Steroid hormone levels in
maternal serum do not differ relative to the baby’s sex and
do not correlate to amniotic levels during the PMW [42].
Therefore, amniotic oestrogens are arguably more relevant
to the current research question than are maternal serum
oestrogens.
A discrepancy in oestrogen levels between the mother
and child could potentially be attributed to the placenta,
which acts as an endocrine regulator of the maternal–foetal
interface and the main source of oestrogen production for
the foetus via the aromatisation of androgens [43]. Several
lines of evidence suggest a contributory role for the placenta
in the aetiology of autism. First, there is increased placental
inﬂammation in autism [44]. Second, there is atypical pla-
cental morphology [45] and increased placental size [46] in
cases of autism and at high familial risk respectively. Third,
complications related to the placenta (pre-eclampsia [47],
Fig. 2 Heatmap and dendrogram
of the pairwise correlations
between the steroid hormones
assayed in amniotic ﬂuid.
Asterisk denotes statistical
signiﬁcance (q < 0.05),




C cortisol, E-S oestrone
sulphate, E2 oestradiol
Fig. 3 Standardised odds ratios (ORs) for autism diagnosis for all
amniotic steroids assayed to date. Each hormone was standardised by
its median and interquartile range, so that a one-unit increase in a
hormone corresponded to the movement from the 25th to the 75th
percentile of its range
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hypertensive disorders [48]) are also more frequent in
pregnancies that lead to autism. As with autism, placental
dysfunction also disproportionately affects males more than
females [49].
Given the high pairwise correlations between many of
the steroid hormones (Fig. 2, Supplementary Table 3), as
well as a lack of difference in aromatisation between cases
and controls, our data suggest that an increase in foetal
oestrogens is secondary to increased activity along the
entirety of the steroidogenic axis in pregnancies that later
result in autism [15]. Interestingly, oestradiol was not sig-
niﬁcantly correlated to testosterone (Pearson’s β= 0.007,
p= 0.9103) despite their proximity in steroidogenesis. This
discrepancy may be because oestrogens are also de novo
produced by the placenta, in addition to being aromatised
from foetal and maternal androgens [43, 50]. Thus, a multi-
systems approach is needed in order to clarify the causes of
elevated foetal oestrogens in autism.
In the brain, oestrogen-mediated signalling on
GABAergic neurons in the hypothalamus is required in
order to suppress the steroidogenic axis [51]. Inefﬁcient
suppression of this axis in autism could be due to inefﬁcient
aromatisation of androgens in the hypothalamus, resistance
to oestrogen signalling and/or dysfunction of the
GABAergic system. Prenatally, foetal genetics (e.g. due to
mutations in aromatase [52] or aromatase activators [53]),
pregnancy complications (e.g. placental size [46]), as well
as maternal risk factors (e.g. PCOS [18]) could all affect
various points in this pathophysiologic pathway. These
speculations would require further testing. Speciﬁcally for
aromatisation, ratios based on circulating hormone levels
may not be sufﬁcient to capture tissue-speciﬁc activity,
since aromatase is differentially regulated by separate pro-
moters in the placenta, the adrenals and the brain [54].
High levels of prenatal oestrogens could dysregulate
many aspects of prenatal endocrinology and affect prenatal
brain development in areas that are not restricted to sexual
differentiation. Several lines of evidence support a wider
role of oestradiol as a ‘neurosteroid’ with many regulatory
properties [55]. For example, disruption of oestrogen sig-
nalling in the developing cerebellum of mice reduces Pur-
kinje cell growth in both males and females, but only
reduces social behaviour in male mice, suggesting that the
cerebellum may react to oestrogenic disruption in a sexually
dimorphic way [56]. In early development, oestradiol
decreases GABAergic signalling [57] and mediates its
postnatal shift from excitation to inhibition [28, 58]. Oes-
trogens both increase the number of spines on embryonic
primary cortical neurons [55] and induce the recruitment of
proteins necessary for excitatory synapse formation, such as
neuroligin-1, NMDA subunit GluN1, and post-synaptic
density protein 95 (PSD-95) to the spines [59]. Higher
levels of prenatal oestrogens might therefore increase the
number of excitatory synapses in the cortex, increasing
the likelihood for autism, as suggested by the excitatory/
inhibitory (E–I) theory of autism [60]. The perceptual
phenotype in autism is characterised by reduced GABAer-
gic inhibition, as shown using paradigms such as binocular
rivalry [61] and attention to detail [62]. Oestrogen signal-
ling could thus be a signiﬁcant modulator of neuronal
inhibition, particularly during early brain development and
the ‘critical period’ of cortical plasticity, which is heavily
reliant on the GABAergic system [63].
Although oestradiol (aromatised from testosterone) is the
main prenatal masculinising agent in most mammals [24],
its role in human sexual differentiation remains unclear.
Men with aromatase deﬁciency have typical development of
their urogenital tract [64], but may have cognitive dis-
abilities, lack a growth spurt, and have atypical secondary
sexual characteristics such as feminised body proportions in
adulthood [65]. Oestrogens may therefore both feminise
and masculinise humans, depending on the target tissue
and developmental milieu. In autism, cognitive styles
and sexually dimorphic neuroanatomy show some mascu-
linised phenotypes [7, 9, 10], but functional connectivity
and physical growth show a mixed pattern of masculine
and feminine shifts [8, 66]. Prenatally though, and parti-
cularly during the masculinisation window, the process of
sexual differentiation is understood to be directionally
masculine over an anatomically and physiologically female
default. The observed high levels of foetal oestrogens
could thus be contributing to developmental cognitive dif-
ferences [10], according to the “extreme male brain” theory
of autism.
There was no statistically signiﬁcant univariate, logistic
association between autism and testosterone or androste-
nedione, which act via the androgen receptor. Mechanisms
through which androgenic signalling could increase autism
likelihood, which may have been missed in this analysis,
include additional androgens or other agonists of the
androgen receptor (e.g. neurosteroids like dehydroepian-
drosterone [67]), interaction effects between androgens and
oestrogens (e.g. coactivation of the androgen receptor by
oestradiol [68]), as well as non-linear associations of
androgens to autism likelihood. Consequently, androgenic
activity may still be an important feature in the development
of autism, as suggested by related clinical comorbidities
[18, 69] and shown in associations of foetal testosterone to
autistic traits in a separate cohort [70].
We could not test whether prenatal oestrogens were
associated with autism likelihood in females as there were
too few diagnosed women in the HBC in this time window.
We plan to test this by expanding the time window. Thus, at
present, our ﬁndings only generalise to males. Furthermore,
comparison of the concentrations of androgens and cortisol
to oestrogens is potentially confounded by the fact that the
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latter were analysed at a later time point and underwent an
additional freeze–thaw cycle. We have attempted to
minimise any potential sources of confounding by using the
same assay methodology with the initial analysis
(LC-MS/MS), as well as reassessing for any differences in
total storage time in this subset of the original cohort
(Table 1).
Another limitation of this study is its reliance on
clinical diagnoses from the Danish Central Psychiatric
Register, which we could not be independently validated.
However, a previous validation study of childhood autism
diagnoses in the Danish Central Psychiatric Register
found that 94% of diagnoses between 1990 and 1999 in
the register were valid using a standardised coding
scheme [71]. Similarly, we cannot be certain about the
source of amniotic steroids, as they could be of foetal,
maternal or placental origin. Foetal plasma and amniotic
ﬂuid are in osmotic equilibrium until the foetal skin is
keratinised (typically by 25 weeks of gestation) [72].
Therefore, steroid concentrations in amniotic ﬂuid accu-
rately reﬂect those in foetal circulation.
In conclusion, we have demonstrated that prenatal oes-
tradiol, oestriol and oestrone are elevated in in boys who
went on to develop autism. This extends our previous
ﬁnding of elevated prenatal steroidogenesis in the same
cohort and provides further evidence for the prenatal steroid
theory of autism [15]. High levels of prenatal oestradiol
contribute to a greater degree to autism likelihood than other
prenatal sex steroids, including testosterone. We conclude
that prenatal oestrogenic excess is a characteristic of autism
and may interact with genetic predisposition to affect
neurodevelopment.
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